## Report of the 24<sup>th</sup> Meeting of the Thyroid Examination Evaluation Subcommittee

Date and Time: Friday, March 28, 2025, 13:30 - 15:30Location:SUGITSUMA KAIKAN, 4th floor meeting room, BOTAN \* Both on-site and onlineAttendees:7 subcommittee membersAgendaAgenda

#### 1. Summary of results of the full-scale survey (up to the 5<sup>th</sup> round survey)

Fukushima Medical University reported finalized summary results of the 5<sup>th</sup> round survey (as of December 31, 2024)<sup>(\*).</sup>

(\*) As for "Document 2-1" of this Oversight Committee meeting, Fukushima Medical University will issue a separate report on it later.

#### 2. Results of the full-scale survey (up to the 5<sup>th</sup> round survey)

A discussion was held on the results of the 5<sup>th</sup> round survey (as of September 30, 2024) by Fukushima Medical University (hereafter referred to as FMU), based on materials prepared by FMU and the opinions of Subcommittee members.

2-1 To compare national detection rates with those of Fukushima Prefecture, annual trends in ageadjusted detection rates were verified using the cancer registry information in Reference 3. After the start of the Thyroid Ultrasound Examination, trends over national rates were confirmed among males and females. In addition, a unified national tabulation (National Cancer Registry), started in FY2016 and proceeding from 2016 to 2020, showed trends for both males and females that have been similar to those of the nation as a whole.

In addition, as in the past, characteristics such as the stage of cancer and the history of detection were confirmed for cases registered in both the Thyroid Ultrasound Examination and cancer registries, as well as for cases registered only in the cancer registries.

#### < Major opinions of the members of the subcommittee >

- · It is important to confirm trends in detection.
- $\cdot$  This time, the graph is for all ages, but from now on, comparisons should be made within the limited age range of those eligible for the Thyroid Ultrasound Examination.
- 2-2 The cumulative detection rate by age group at the time of the disaster was graphed to show changes in monitoring effect over time (Ref 4-1 to 4-2). Detection rates were higher in older age groups, regardless of whether the cases were drawn from preliminary examinations or cancer registries only.

#### < Major opinions of the members of the subcommittee >

- In the Chernobyl nuclear accident, a notable prevalence of thyroid cancer was observed in radiation-sensitive young children (especially those under 5 years of age). Still, no significant risk was observed among those in their 20s. In light of this history, we can confirm that Fukushima Prefecture has not seen a high prevalence of thyroid cancer in radiation-sensitive younger age groups.

- In the cohort aged 15 years or older at the time of the disaster in Figure 4-1-2 (1-7), limited to cases detected by the Thyroid Ultrasound Examination full-scale survey, there are marked increases at ages 25 and 30, indicating the effect of the implementation of Age 25 and Age 30 Survey examinations. In addition, flattening of the curve from the late 20s in Figure 4-2-3 (1-10), which is limited to cases registered only in the cancer registry, is different from the usual trend in which the detection rate increases with age, suggesting a monitoring effect associated with the Thyroid Ultrasound Examination.

#### 55\_1(EN)\_Report of the 24th Meeting of the Thyroid Examination Evaluation Subcommittee

2-3 A case-control study within a cohort was conducted to examine the association between individual estimated radiation doses and detection of malignancy or suspicion for malignancy (Ref. 5-1 to 5-12)  $(^{*2})$ .

As it was through the 4<sup>th</sup> round full-scale survey, analysis was limited to the evacuation area and Hamadori,<sup>\*(1)</sup> where doses of 10 mSv or higher were within the dose distribution. As a result, no significant association was found in the evacuation area, but a significant association was found in the Hamadori area at 10 mSv or higher. In addition, inspection results do not indicate an increase in the number of cases above 10 mSv through the 4<sup>th</sup> round full-scale survey, but this may be an effect of the way the controls were selected.

\*1 Three cities and towns in Hamadori (Iwaki City, Soma City, Shinchi Town), not including evacuation areas

- \*2 Ref 5-1 to 5-6: Cases registered only in cancer registries are not included.
- (5-4: Matching Model 2 limited to the evacuation area of + Hamadori, 5-5: limited to the evacuation area, 5-6: limited to Hamadori) Ref 5-7 to 5-12: <u>including</u> cases registered only in cancer registries.
- (5-10: Matching Model 2, limited to the evacuation area + Hamadori, 5-11: limited to the evacuation area, 5-12: limited to Hamadori

#### <Major opinions of the members of the subcommittee>

- Rather than focusing only on the odds ratio, the data can be misleading if one does not pay attention to the way controls were selected (ratio to the control population<sup>\*1</sup> or the case group<sup>\*2</sup>) and the characteristics of the population.
- The intention of limiting analyses by regions is to reduce biases such as the participation rate of the confirmatory examination, the cytological diagnosis implementation rate, and the timing of the examination, since the examinations are conducted over multiple years. Evacuation areas should be watched most closely because of the high confirmatory examination participation rate and cytological diagnosis implementation rate due to the residents' level of anxiety.
- Because case-control studies are affected by these population characteristics and numbers, trends should be checked in parallel with cohort studies, using the Kaplan-Meier method.
- When verifying the effects of radiation dose, the analysis should be mainstreamed with the addition of cases registered only in cancer registries that are detected clinically, to attenuate the monitoring effect of the Thyroid Ultrasound Examination.
- 2-4 The Kaplan-Meier method, mainly used for survival time analysis, was used in Reference 6 from the perspective of observation over time using the person-year method for observing the cumulative detection rate of malignant or suspicious for malignancy cases.

Ref 6-1 shows the data by gender, Ref 6-2 shows the data by age group at the time of the disaster, and Ref 6-3 shows the data by thyroid equivalent dose in 3 categories of Hamadori and the evacuation areas.

The graphs in Exhibit 6-4 and Exhibit 6-5 show thyroid equivalent doses in the three areas of residence at the time of the earthquake and the three thyroid equivalent dose categories in Hamadori. No significant differences were found in Data 6-3 to 6-5.

#### <Major opinions of the members of the subcommittee>

• In the case-control study, there was a significant association at 10 mSv or more limited to Hamadori, but no such association was found using Kaplan-Meier analysis, which could be interpreted as a coincidence due to the way the controls were selected.

## Thyroid Ultrasound Examination Results Summary

Exa	minations	Preliminary Examination	Full-scale Survey 1	Full-scale Survey 2	Full-scale Survey 3	Full-scale Survey 4	Full-scale Survey 5	Age 25	Age 30
		(The 1st-round survey)	(The 2nd-round survey)	(The 3st round survey)	(The 4th-round survey)	(The 5th-round survey)	(The 6th-round survey)	Survey	Survey
Items		2011-2013	2014-2015	2016-2017	2018-2019	2020-2022	2023-2024	Starting from 2017	Starting from 2022
Eligible persons		367,637	381,237	336,667	294,228	252,936	211,903	149,843	44,489
Participa	ation Rate	81.7%	71.0%	64.7%	62.3%	45.1%	25.0%	8.6%	6.7%
	A1	51.5%	40.2%	35.1%	33.6%	28.8%	27.0%	42.3%	42.8%
Results	A2	47.8%	59.0%	64.2%	65.6%	70.0%	71.6%	52.2%	48.2%
Results	В	0.8%	0.8%	0.7%	0.8%	1.2%	1.5%	5.5%	9.0%
	С	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		As of March 31, 2018	As of March 31, 2021	As of March 31, 2021	As of June 30, 2022	As of December 31, 2024	As of September 30, 2024	As of September 30, 2024	As of September 30, 2024

#### Report on the TUE Full-Scale Survey (fifth-round survey)

As of December 31, 2024

#### 1. Summary

#### 1.1 Purpose

To monitor the long-term health of children, we are continuing the Full-Scale Survey (fifth-round survey), following the Preliminary Baseline Survey for initial assessment of thyroid glands, and prior Full-Scale Surveys (second, third, and fourth-round surveys) to continuously assess the status of thyroid glands.

#### 1.2 Eligible persons

All Fukushima residents who were approximately 18 years old or younger at the time of the earthquake (those born between April 2, 1992, and April 1, 2012).

#### **1.3 Implementation Period**

FY2020 and FY2022, starting in April 2020:

- 1.3-1 For those 18 years old or younger The examination was conducted over three years, from FY2020 through FY2022.
- 1.3-2 For those 19 years old or older

The examination was conducted on an age-group basis (i.e., school grade). FY2020: those born in FY1998 and FY2000 FY2021: those born in FY1999 and FY2001 FY2022: no eligible persons

1.3-3 For those 25 years old or older
Those older than 20 are recommended to receive the examination every 5 years at the ages of 25, 30, and so on (Age 25 and Age 30 Surveys).
FY2020: those born in FY1995
FY2021: those born in FY1996
FY2022: those born in FY1992 and FY1997
The results of the Age 25 and Age 30 Surveys will be reported separately.

# **1.4 Implementing Organizations** (number of medical facilities with agreements for the implementation of thyroid examinations as of December 31, 2024)

Fukushima Prefecture commissioned Fukushima Medical University (FMU) to conduct the Survey in cooperation with organizations inside and outside Fukushima for the convenience of participants.

1.4-1 Primary examination facilities	
In Fukushima Prefecture	85 medical facilities
Outside Fukushima Prefecture	150 medical facilities

1.4-2 Confirmatory examination facilitiesIn Fukushima Prefecture7 medical facilities, including FMUOutside Fukushima Prefecture42 medical facilities

#### 1.5 Methods

1.5-1 Primary examination

Ultrasonography of the thyroid gland

1.4.1 Drimon (avamination facilities

Assessments are made by specialists based on the following criteria:

- Grade A
- A1: No nodules/cysts

A2: Nodules  $\leq$  5.0 mm or cysts  $\leq$  20.0 mm

- Grade B

B: Nodules  $\geq$  5.1 mm or cysts  $\geq$  20.1 mm

Some A2 results may be reclassified as B results when clinically indicated.

-Grade C

C: Urgent need for confirmatory examination, judging from the condition of the thyroid gland.

## 1.5-2 Confirmatory examination

Ultrasonography of the thyroid gland, blood and urine tests, and fine needle aspiration cytology (FNAC) if needed for those with B or C test results.

Priority is given to those in urgent clinical need. A medical follow-up may be recommended based on confirmatory exam results.

1.5-3 Flow chart




Figure 1: Flow chart

## 1.6 Municipalities Surveyed

The municipalities where examinations (for those 18 years old or younger) were carried out in FY2020 and FY2022 are as follows:




Figure 2 Municipalities covered for primary examinations at elementary and junior high schools




Figure 3 Municipalities covered for primary examinations at high schools and other facilities

The data will be compiled biannually, per the initial plan.

## 2. Results as of December 31, 2024

#### 2.1 Results of the Primary Examination

2.1-1 Implementation status

The primary examination was completed for 113,959 participants (45.1%) by December 31, 2024. (Refer to Appendices 1 and 2 for the participation and progress summaries by municipalities in Fukushima and other prefectures.)

The results of 113,959 participants (100.0%) have been finalized, and individual reports have been sent to them. (See Appendix 3 for the results by municipalities.)

Of these, 32,846 (28.8%) had Grade A1 results, 79,767 (70.0%) had Grade A2, 1,346 (1.2%) had Grade B, and none had Grade C.

		Partici	Participants (persons)			Participants with finalized results (persons)									
	Eligible persons			Those who					De	etails by gr	ade (%)				
			Participation rate (%)		Judgment rate (%)		А			Those referred to confirmatory			exam		
				outside Fukushima			A1		A2		В		(	2	
	а	b	(b/a)	1 ultuoniniu	С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/c)	
FY2020	144,902	69,179	(47.7)	5,500	69,179	(100.0)	19,999	(28.9)	48,432	(70.0)	748	(1.1)	0	(0.0)	
FY2021	108,034	44,780	(41.4)	2,471	44,780	(100.0)	12,847	(28.7)	31,335	(70.0)	598	(1.3)	0	(0.0)	
Total	252,936	113,959	(45.1)	7,971	113,959	(100.0)	32,846	(28.8)	79,767	(70.0)	1,346	(1.2)	0	(0.0)	

Table 1: Progress and results of the primary examination

#### Table 2: Number and proportion of participants with nodules/cysts (See Appendix 4 for details.)

	Dortigingsto with	Participants with nodules / cysts (%)										
	Participants with finalized results		Noc	lules		Cysts						
		≥ 5.1mm		≤ 5.0mm		≥ 20.	1mm	≤ 20.0mm				
	а	b	(b/a)	с	(c/a)	d	(d/a)	е	(e/a)			
FY2020	69,179	748	(1.1)	381	(0.6)	1	(0.0)	48,848	(70.6)			
FY2021	44,780	598	(1.3)	284	(0.6)	0	(0.0)	31,678	(70.7)			
Total	113,959	1,346	(1.2)	665	(0.6)	1	(0.0)	80,526	(70.7)			

· Proportions are rounded to a lower decimal place. This applies to other tables as well.

- Those who receive the examination at 5-year intervals (born between FY1992 and FY1997: Age 25 and Age 30 Surveys) are excluded and will be reported separately.
- Examinations for those born in FY1995 (approx. 21,000) took place in FY2020; for those born in FY1996 (approx. 21,000), FY2021; and for those born in FY1992 (approx. 23,000) and FY1997 (approx. 20,000), FY2022.

#### 2.1-2 Participation rate by age group

Table 3 shows the participation rate for each age group as of April 1 of each fiscal year.

			Total		Age group	
	Age group*			8 to 11 years old	12 to 17 years old	18 to 24 years old
FY2020	Eligible persons	(a)	144,902	37,105	61,911	45,886
	Participants	(b)	69,179	27,925	36,161	5,093
	Participation rate (%)	(b/a)	47.7	75.3	58.4	11.1
	Age group*			9 to 11 years old	12 to 17 years old	18 to 24 years old
FY2021	Eligible persons	(a)	108,034	19,771	45,059	43,204
	Participants	(b)	44,780	14,152	25,688	4,940
	Participation rate (%)	(b/a)	41.4	71.6	57.0	11.4
	Eligible persons	(a)	252,936	56,876	106,970	89,090
Total	Participants	(b)	113,959	42,077	61,849	10,033
	Participation rate (%)	(b/a)	45.1	74.0	57.8	11.3

Table 3: Participation rates by age group

\* Age groups are based on ages as of April 1 of each fiscal year.

#### 2.1-3 Comparison of the fourth- and fifth-round survey results

Table 4 compares the results of two Full-Scale Surveys (fourth- and fifth-round surveys).

Among 106,592 (sum of \*1) participants with Grade A (A1 and A2) results in the fourth-round survey, 105,825 (sum of \*2, 99.3%) had Grade A (A1 and A2) results, and 767 (sum of \*3, 0.7%) had Grade B results in the fifth-round survey.

Among 546 participants with Grade B results in the fourth-round survey, 104 (sum of \*4, 19.0%) had Grade A (A1 and A2) results, and 442 (81.0%) had Grade B results in the fifth-round survey.

Table 4: Comparison of the fourth- and fifth-round surveys

			Results of the	F	Results of the fift	h-round survey*	*
			fourth-round	A	A Contraction of the second se	В	С
			survey*	A1	A2	D	C
			а	b	С	d	е
			(%)	(b/a)	(c/a)	(d/a)	(e/a)
		A1	<b>34,598</b> *1	<b>23,881</b> *2	10,582 *2	<b>135</b> *3	0
	А		(100.0)	(69.0)	(30.6)	(0.4)	(0.0)
	A	A2	<b>71,994</b> *1	6,645 *2	<b>64,717</b> *2	<b>632</b> *3	0
Results of		A2	(100.0)	(9.2)	(89.9)	(0.9)	(0.0)
the fourth-		в	546	11 *4	93 *4	442	0
round survey		Ъ	(100.0)	(2.0)	(17.0)	(81.0)	(0.0)
Tourio Survey		С	0	0	0	0	0
		C	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	Did not participate		6,821	2,309	4,375	137	0
			(100.0)	(33.9)	(64.1)	(2.0)	(0.0)
	Total		113,959	32,846	79,767	1,346	0
	Total		(100.0)	(28.8)	(70.0)	(1.2)	(0.0)

\*Results of the fourth-round survey are from fifth-round survey participants with finalized results, not the breakdown of all fourth-round survey participants.

\*\*Results of the fifth-round survey participants diagnosed for each grade in the fourth-round survey.

## 2.2 Results of the Confirmatory Examination

#### 2.2-1 Implementation status

By December 31, 2024, of 1,346 eligible persons, 1,116 (82.9%) had participated in the confirmatory examination, and 1,101 (98.7%) had completed the entire procedure. (See Appendix 5 for the implementation status of the confirmatory examinations by area.)

Of those 1,101 participants, 104 (A1: 7, A2: 97) (9.4%) were confirmed to meet A1 or A2 diagnostic criteria by primary examination standards (including those with other thyroid conditions). After the detailed examination, 997 (90.6%) were confirmed to be outside the A1 or A2 criteria.

	Those	Partic	•		Those with finalized results (persons)										
	referred to confirmatory	(persons) (%) Participation		Determination rate (%)		A1		A2		Other that		n A1 or A2			
	exams	F	Rate (%)	rate (%)		2.1						FNAC			
	а	b	(b/a)	с	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/f)		
FY2020	748	627	(83.8)	618	(98.6)	4	(0.6)	64	(10.4)	550	(89.0)	67	(12.2)		
FY2021	598	489	(81.8)	483	(98.8)	3	(0.6)	33	(6.8)	447	(92.5)	34	(7.6)		
Total	1,346	1,116	(82.9)	1,101	(98.7)	7	(0.6)	97	(8.8)	997	(90.6)	101	(10.1)		

Table 5: Progress and results of the confirmatory examination

2.2-2 Results of fine needle aspiration cytology (FNAC)

Among those who underwent FNAC, 50 participants had nodules classified as malignant or suspicious for malignancy: 13 were male, and 37 were female. Participants' ages at the confirmatory examination ranged from 12 to 24 years (mean age:  $17.3 \pm 2.9$  years). The tumor diameters were from 5.4 mm to 46.7 mm (mean tumor diameter:  $14.0 \pm 8.2$  mm).


Of these 50 participants, 38 had Grade A (A1:11, A2:27), 6 had Grade B results in the fourth-round survey, and the remaining 6 did not participate. Among 27 participants with Grade A2, 1 met nodule, 23 met cyst, and 3 met both cyst and nodule criteria.

Table 6: Results of FNAC (The mean age and mean tumor size in parentheses indicate the range.)


A. Municipalities surveyed in FY2020	
Malignant or suspicious for malignancy	30*
<ul> <li>Male to female ratio</li> </ul>	6:24
・Mean age ± SD (min-max)	17.5 ± 3.3 (12–24)
	$6.6 \pm 3.3 (1-12)$ at the time of the earthquake
<ul> <li>Mean tumor size ± SD (min-max)</li> </ul>	11.2 ± 4.9 mm (5.4–30.1 mm)
B. Municipalities surveyed in FY2021	
Malignant or suspicious for malignancy	20*
<ul> <li>Male to female ratio</li> </ul>	7:13
・Mean age ± SD (min-max)	17.1 ± 2.1 (13–21)
	$5.3 \pm 2.8$ (0–10) at the time of the earthquake
・Mean tumor size±SD (min-max)	18.1 ±10.3 mm (7.1–46.7 mm)
C. Total	
Malignant or suspicious for malignancy	50*
Male to female ratio	13:37
・Mean age ± SD (min-max)	17.3 ± 2.9 (12–24)
	$6.1 \pm 3.2 (0-12)$ at the time of the earthquake
・Mean tumor size ± SD (min-max)	14.0 ± 8.2 mm (5.4–46.7 mm)

\* Appendix 6 shows surgical cases.

2.2-3 Age distribution of malignant or suspected malignant cases diagnosed by FNAC The age distribution of 50 people with malignant or suspected malignant nodules based on their age as of March 11, 2011, is in Figure 4. The age distribution based on their age at the time of confirmatory examination is in Figure 5.



Note: Those aged between 13 and 18 at the time of the disaster are not included in the fifth-round survey participants. The horizontal axis begins at -1, including those born between April 2, 2011, and April 1, 2012. \*Those born between March 12 and April 1, 2011, are included in age 0.






Figure 5: Age distributions as of the date of confirmatory examination

2.2-4 Basic Survey results for those deemed malignant or suspicious for malignancy by FNAC Of those 50 people with malignant or suspicious findings, 29 (58.0%) had participated in the Basic Survey (for external radiation dose estimation), and all 29 received their results. The highest effective dose documented was 2.4 mSv.

Effective		Age at the time of the earthquake													
dose	0–5		6–10		11–15		16–18		Total						
(mSv)	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female					
< 1	2	5	2	7	0	3	0	0	4	15					
< 2	1	1	1	2	1	1	0	0	3	4					
< 5	0	2	0	0	1	0	0	0	1	2					
< 10	0	0	0	0	0	0	0	0	0	0					
< 20	0	0	0	0	0	0	0	0	0	0					
≥ 20	0	0	0	0	0	0	0	0	0	0					
Total	3	8	3	9	2	4	0	0	8	21					

Table 7: A breakdown of dose estimates for Basic Survey participants




Figure 6: Effective dose distribution of the Basic Survey participants

## 2.2-5 Blood test and urinary iodine test results

	FT4 <sup>1)</sup> (ng/dL)		TSH <sup>3)</sup> (µIU/mL)	Tg <sup>4)</sup> (ng/mL)	TgAb <sup>5)</sup> (IU/mL)	TPOAb <sup>6)</sup> (IU/mL)
Reference Range	eference Range 0.95–1.74 <sup>7)</sup>		0.340-3.880 <sup>7)</sup>	≤ 33.7	< 28.0	< 16.0
Malignant or suspicious : 50	1.2 ± 0.2 (4.0%	) $3.5 \pm 0.4$ (4.0%)	1.3±0.7 (10.0%)	78.0±306.1 (22.0%)	14.0%	14.0%
Other : 956	1.2 ± 0.2 (5.3%	) 3.6 ± 0.8 (7.4%)	1.3±1.1 (8.6%)	30.3±79.8 (15.8%)	8.9%	7.5%

#### Table 8: Blood test results

Table 9: Urinary iodine test results <sup>8)</sup>

							(µg/day)
			Minimum	25th percentile	Median	75th percentile	Maximum
Malignant or suspicious	:	47	36	127	175	410	2,471
Other		942	21	113	193	331	12,670

- 1) FT4: free thyroxine, thyroid hormone binding 4 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).
- 2) FT3: free triiodothyronine, thyroid hormone binding 3 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).
- TSH: thyroid-stimulating hormone; higher among patients with Hashimoto's disease and lower with Graves' disease.
- 4) Tg: thyroglobulin; higher when thyroid tissue is destroyed or neoplastic tissue produces thyroglobulin.
- 5) TgAb: anti-thyroglobulin antibody; higher among patients with Hashimoto's disease or Graves' disease.
- 6) TPOAb: anti-thyroid peroxidase antibody; higher among patients with Hashimoto's disease or Graves' disease.
- 7) Reference intervals vary according to age.
- 8) Due to the temporary suspension of reagents, the urinary iodine tests have been suspended since March 8, 2024, as of December 31, 2024.

#### 2.2-6 Confirmatory examination results by area

The percentages of those with malignant or suspicious findings were 0.04% in the 13 municipalities of the nationally designated evacuation zone and Nakadori, 0.06% in Hamadori, and 0.03% in Aizu.

	The fifth- round survey participants (persons)	Those referred to confirmatory exam (persons) and rate (%)		Those who received the confirmatory exam (persons)	Those with m suspicious (persons) an	findings
	а	b	b/a		с	c/a
13 municipalities <sup>1)</sup>	14,787	156	1.1	129	6	0.04
Nakadori <sup>2)</sup>	65,595	739	1.1	617	28	0.04
Hamadori <sup>3)</sup>	20,786	293	1.4	236	12	0.06
Aizu <sup>4)</sup>	12,791	158	1.2	134	4	0.03
Total	113,959	1,346	1.2	1,116	50	0.04

#### Table 10: Confirmatory examination results by area

1) Tamura City, Minamisoma City, Date City, Kawamata Town, Hirono Town, Naraha Town, Tomioka Town, Kawauchi Village, Okuma Town, Futaba Town, Namie Town, Katsurao Village, Iitate Village

- 2) Fukushima City, Koriyama City, Shirakawa City, Sukagawa City, Nihonmatsu City, Motomiya City, Koori Town, Kunimi Town, Otama Village, Kagamiishi Town, Tenei Village, Nishigo Village, Izumizaki Village, Nakajima Village, Yabuki Town, Tanagura Town, Yamatsuri Town, Hanawa Town, Samegawa Village, Ishikawa Town, Tamakawa Village, Hirata Village, Asakawa Town, Furudono Town, Miharu Town, Ono Town
- 3) Iwaki City, Soma City, Shinchi Town
- 4) Aizuwakamatsu City, Kitakata City, Shimogo Town, Hinoemata Village, Tadami Town, Minamiaizu Town, Kitashiobara Village, Nishiaizu Town, Bandai Town, Inawashiro Town, Aizubange Town, Yugawa Village, Yanaizu Town, Mishima Town, Kaneyama Town, Showa Village, Aizumisato Town

## Table 11Percentage of grade B • C and malignant or suspicious for malignancy cases<br/>by region in the 5th round survey

As of	December	31,	2024
-------	----------	-----	------

				710 01 0		, 2021
		13 municipalities "1	Nakadori *2	Hamadori *3	Aizu *4	Total
Covered population		32,140	139,069	48,283	33,444	252,936
Number of participants undergoing primary examination <b>*a</b>		14,787	65,595	20,786	12,791	113,959
Mean age at the time of disaster (Standard deviation) Overall		3.8(3.1)	3.6 (3.0)	3.8(3.2)	3.3(2.9)	-
Mean age at the time of disaster (Standard deviation) Female		3.9(3.2)	3.7 (3.1)	3.9(3.3)	3.4(3.0)	-
Mean age at the time of disaster (Standard deviation) Male		3.7(3.0)	3.5 (3.0)	3.6(3.1)	3.2(2.8)	-
Mean age at the time of examination (Standard deviation) Overall		13.9(3.4)	14.1 (3.1)	15.1(3.0)	14.6(2.9)	-
Mean age at the time of examination (Standard deviation) Female		14.0(3.5)	14.2 (3.2)	15.3(3.0)	14.7(3.0)	-
Mean age at the time of examination (Standard deviation) Male		13.8(3.3)	14.0 (3.1)	15.0(2.9)	14.4(2.8)	-
Percentages of female participants on primary examination	%	50.1	49.8	49.9	50.0	49.9
Number of participants with grade B · C <b>*b</b>		156	739	293	158	1,346
Percentages of participants with grade B · C results (Participants with grade B · C results/primary exam participants) <b>*b/a</b>	%	1.05	1.13	1.41	1.24	1.18
Number of finalized results of the confirmatory examination ${}^{\star c}$		126	608	235	132	1,101
Participation rate of the confirmatory examination (Confirmatory exam finalized results/participants with grade $B \cdot C$ ) *c/b	%	80.8	82.3	80.2	83.5	81.8
Number of participants underwent cytological examination (FNAC) <b>*d</b>		8	66	18	9	101
Participation rate of FNAC *d/c (Number of FNACs/number of finalized results of the confirmatory exam)	%	6.3	10.9	7.7	6.8	9.2
Participation rate of FNAC *d/a (Number of FNACs /number of participants of the primary exam)	%	0.05	0.10	0.09	0.07	0.09
Cases of malignant or suspicious for malignancy <b>*e</b>		6	28	12	4	50
Cases of malignant or suspicious for malignancy /number of FNACs <b>*e/d</b>	%	75.0	42.4	66.7	44.4	49.5
Percentages of malignant or suspicious for malignancycases : 100,000 per		40.6	42.7	57.7	31.3	43.9
capita *e/a	(%)	(0.041)	(0.043)	(0.058)	(0.031)	(0.044)

\*The table data above does not include duplicates or results that have not been finalized.

- 1) Tamura City, Minamisoma City, Date City, Kawamata Town, Hirono Town, Naraha Town, Tomioka Town, Kawauchi Village, Okuma Town, Futaba Town, Namie Town, Katsurao Village, Iitate Village
- 2) Fukushima City, Koriyama City, Shirakawa City, Sukagawa City, Nihonmatsu City, Motomiya City, Koori Town, Kunimi Town, Otama Village, Kagamiishi Town, Tenei Village, Nishigo Village, Izumizaki Village, Nakajima Village, Yabuki Town, Tanagura Town, Yamatsuri Town, Hanawa Town, Samegawa Village, Ishikawa Town, Tamakawa Village, Hirata Village, Asakawa Town, Furudono Town, Miharu Town, Ono Town
- 3) Iwaki City, Soma City, Shinchi Town
- 4) Aizuwakamatsu City, Kitakata City, Shimogo Town, Hinoemata Village, Tadami Town, Minamiaizu Town, Kitashiobara Village, Nishiaizu Town, Bandai Town, Inawashiro Town, Aizubange Town, Yugawa Village, Yanaizu Town, Mishima Town, Kaneyama Town, Showa Village, Aizumisato Town

#### Table 11: The comparison results by area

The mean age of primary examination participants at the time of the earthquake was highest in the "13 municipalities," and "Hamadori," followed by "Nakadori," and "Aizu."

The mean age of primary examination participants at the time of examination was highest in "Hamadori," followed by "Aizu," "Nakadori," and "13 municipalities."

The "13 municipalities" had the highest proportion of female primary examination participants, followed by "Aizu," "Hamadori," and "Nakadori."

The following insights are provided by comparing the results of an analysis of the 113,959 individuals who underwent the primary examination without considering factors such as age, gender, examination interval, participation rate by age group, and participation rate of the confirmatory examination.

The percentages of grade B and C were highest in the following order: "Hamadori," "Aizu," "Nakadori," and "13 municipalities."

The percentages of participants having malignant or suspicious for malignancy were in descending order: "Hamadori," "Nakadori," "13 Municipalities," and "Aizu."

#### 3. Mental Health Care

We have been providing the following support for thyroid examination participants.

#### 3.1 Support for Primary Examination Participants

After the examination, medical doctors offer person-to-person explanations of examination results, showing ultrasound images in private consultation booths at examination venues set up in public facilities.

Consultation booths were set up at all venues for examinations conducted in and after April 2020; as of Devember 31, 2024, all 2,759 participants (100%) have visited these consultation booths.

#### 3.2 Outreach programs (on-location lectures and information sessions)

We have conducted on-location lectures and information sessions to support participants and their parents/guardians to deepen their understanding of the thyroid examination.

From April 2020 to March 31, 2023, 607 people participated in sessions offered at 11 locations: 3 elementary schools, 4 junior high schools, and 4 high schools.

#### 3.3 Support for Confirmatory Examination Participants

A support team has been established within Fukushima Medical University to offer mental health support to those undergoing the confirmatory (secondary) examination to address their concerns and anxiety, as well as to answer questions and provide guidance via web consultation.

Since the start of the fifth-round survey, 402 participants (127 males and 275 females) have received support as of December 31, 2024. The number of support sessions provided, including telephone counseling, was 710 in total. Of these, 397 (55.9%) received support at the participants' first examination and 313 (44.1%) at subsequent examinations.

For those who proceed to regular insured medical care, the support team continues to provide support in cooperation with teams of medical staff at hospitals.

Appendix 1: Implementation status of the TUE primary examination, by the municipality As of December 31, 2024

	Number of eligible persons	Participants (persons)	Participated	Participation rate(%)		articipants and p rate by age group <sup>2)</sup>	participation	Participants living outside Fukushima	%
	а	b	outside Fukushima <sup>1)</sup>	b/a	8–11	12–17	18–24	c <sup>3)</sup>	c/b
Municipalities surve	eved in FY202	0						L1	
				47.0	238	431	70	50	7.0
Kawamata	1,567	739	14	47.2	32.2	58.3	9.5	58	7.8
Namie	2,478	954	235	38.5	210	547	197	245	25.7
Name	2,470	504	200	00.0	22.0	57.3	20.6	240	20.7
litate	731	346	20	47.3	88	202	56	27	7.8
					25.4	58.4	16.2		
Minamisoma	8,849	3,975	571	44.9	1,201 30.2	2,253 56.7	521 13.1	669	16.8
					1,143	2,284	612		
Date	7,412	4,039	166	54.5	28.3	56.5	15.2	183	4.5
Tamura	4 577	0.001	52	40.9	803	1,227	251	97	4.3
Tamura	4,577	2,281	52	49.8	35.2	53.8	11.0	97	4.3
Hirono	647	289	28	44.7	68	166	55	27	9.3
	0	200			23.5	57.4	19.0		0.0
Naraha	916	369	44	40.3	73	221	75	54	14.6
					19.8	59.9 412	20.3		
Tomioka	1,980	715	122	36.1	153 21.4	412 57.6	150 21.0	134	18.7
					21.4	57.0	19		
Kawauchi	225	98	7	43.6	20.4	60.2	19.4	10	10.2
<u>.</u>					145	392	133	105	
Okuma	1,771	670	117	37.8	21.6	58.5	19.9	125	18.7
Futaba	839	247	48	29.4	51	155	41	57	23.1
Fulapa	039	247	40	29.4	20.6	62.8	16.6	57	23.1
Katsurao	148	65	3	43.9	14	39	12	7	10.8
			-		21.5	60.0	18.5		
Fukushima	37,320	18,605	1,416	49.9	4,862	11,047	2,696	1,434	7.7
					26.1 1,126	59.4 2,156	14.5		
Nihonmatsu	6,920	3,713	160	53.7	30.3	58.1	431 11.6	163	4.4
					663	1,302	246		
Motomiya	4,232	2,211	78	52.2	30.0	58.9	11.1	81	3.7
01	4 400	004	10	00.7	214	384	83		0.4
Otama	1,122	681	18	60.7	31.4	56.4	12.2	14	2.1
Koriyama	45.739	20,620	1,966	45.1	4,729	12,879	3,012	1,996	9.7
Ronyama	40,709	20,020	1,900	43.1	22.9	62.5	14.6	1,990	5.1
Koori	1,375	789	25	57.4	224	467	98	33	4.2
Room	1,010	100	20		28.4	59.2	12.4		1.2
Kunimi	1,022	559	20	54.7	126	349	84	24	4.3
					22.5	62.4	15.0		
Tenei	728	332	19	45.6	95	180	57	12	3.6
					28.6	54.2 2.366	17.2		
Shirakawa	8,566	4,240	257	49.5	1,229 29.0	2,366 55.8	645 15.2	262	6.2
					399	740	206		
Nishigo	2,856	1,345	77	47.1	29.7	55.0	15.3	80	5.9
			_		105	245	44		
Izumizaki	893	394	7	44.1	26.6	62.2	11.2	11	2.8
Miharu	1,989	903	30	45.4	218	525	160	35	3.9
winiaru	1,909	903	30	40.4	24.1	58.1	17.7	30	3.9
Subtotal	144,902	69,179	5,500	47.7	18,197	41,028	9,954	5,838	8.4
	,	20,0	5,000		26.3	59.3	14.4	2,000	0.1

\*1) The number of participants who received the examination at facilities outside Fukushima (as of November 30, 2024).

\*2) Split cells show the number of participants above the corresponding percentage.

\*3) The number of participants who have resident registration outside Fukushima.

•Age groups are based on participants' age at the Full-Scale Survey (fifth-round survey). This applies to other tables hereafter.

	Number of eligible persons	Participants (persons)	Participated outside	Participation rate(%)		articipants and rate by age group <sup>2)</sup>	participation	Participants living outside Fukushima	%
	а	b	Fukushima <sup>1)</sup>	b/a	8–11	12–17	18–24	c <sup>3)</sup>	c/b
Municipalities surve	yed in FY202	1							
Iwaki	42,529	18,581	1,371	43.7	2,130 11.5	12,306 66.2	4,145 22.3	1,368	7.4
Sukagawa	10,705	4,583	181	42.8	773 16.9	3,055 66.7	755 16.5	196	4.3
Soma	4,771	1,781	167	37.3	325 18.2	1,204 67.6	252 14.1	192	10.8
Kagamiishi	1,834	818	28	44.6	142 17.4	552 67.5	124 15.2	25	3.1
Shinchi	983	424	29	43.1	61 14.4	279 65.8	84 19.8	35	8.3
Nakajima	706	266	9	37.7	54 20.3	169 63.5	43 16.2	7	2.6
Yabuki	2,326	978	22	42.0	217 22.2	639 65.3	122 12.5	28	2.9
Ishikawa	1,860	790	25	42.5	161 20.4	489 61.9	140 17.7	28	3.5
Yamatsuri	685	306	13	44.7	66 21.6	207 67.6	33 10.8	8	2.6
Asakawa	913	409	21	44.8	73 17.8	268 65.5	68 16.6	17	4.2
Hirata	838	371	9	44.3	86 23.2	220 59.3	65 17.5	7	1.9
Tanagura	2,049	847	32	41.3	178 21.0	562 66.4	107 12.6	39	4.6
Hanawa	1,070	419	8	39.2	83 19.8	262 62.5	74 17.7	11	2.6
Samegawa	457	191	4	41.8	43 22.5	129 67.5	19 9.9	4	2.1
Ono	1,252	502	7	40.1	107 21.3	339 67.5	56 11.2	6	1.2
Tamakawa	920	386	9	42.0	68 17.6	258 66.8	60 15.5	6	1.6
Furudono	692	337	17	48.7	71 21.1	199 59.1	67 19.9	11	3.3
Hinoemata	75	16	2	21.3	3 18.8	11 68.8	2 12.5	0	0.0
Minamiaizu	1,788	666	20	37.2	148 22.2	445 66.8	73 11.0	23	3.5
Kaneyama	114	38	0	33.3	6 15.8	25 65.8	7 18.4	0	0.0
Showa	101	33	5	32.7	9 27.3	22 66.7	2 6.1	5	15.2
Mishima	131	45	0	34.4	12 26.7	24 53.3	9 20.0	1	2.2
Shimogo	646	216	3	33.4	41 19.0	143 66.2	32 14.8	4	1.9
Kitakata	5,939	2,227	66	37.5	393 17.6	1,515 68.0	319 14.3	77	3.5
Nishiaizu	618	201	5	32.5	43 21.4	133 66.2	25 12.4	4	2.0
Tadami	475	212	5	44.6	38 17.9	150 70.8	24 11.3	6	2.8
Inawashiro	1,760	696	23	39.5	137 19.7	454 65.2	105 15.1	22	3.2
Bandai	415	159	9	38.3	32 20.1	106 66.7	21 13.2	8	5.0
Kitashiobara	385	163	6	42.3	32 19.6	111 68.1	20 12.3	7	4.3
Aizumisato	2,371	987	25	41.6	179 18.1	633 64.1	175 17.7	30	3.0
Aizubange	2,012	790	27	39.3	140 17.7	504 63.8	146 18.5	37	4.7
Yanaizu	393	148	3	37.7	31 20.9	98 66.2	19 12.8	4	2.7
Aizuwakamatsu	15,770	5,983	316	37.9	950 15.9	4,003 66.9	1,030 17.2	346	5.8
Yugawa	451	211	4	46.8	38 18.0	130 61.6	43 20.4	6	2.8
Subtotal	108,034	44,780	2,471	41.4	6,870 15.3	29,644 66.2	8,266 18.5	2,568	5.7
Total	252,936	113,959	7,971	45.1	25,067 22.0	70,672 62.0	18,220 16.0	8,406	7.4

Appendix 2: Implementation status of the TUE primary examination, by prefecture

## As of November 30, 2024

Prefecture	Number of medical facilities	Participants (persons)	Prefecture	Number of medical facilities	Participants (persons)	Prefecture	Number of medical facilities	Participants (persons)
Hokkaido	7	195	Fukui	1	12	Hiroshima	2	17
Aomori	3	94	Yamanashi	2	65	Yamaguchi	1	14
lwate	4	182	Nagano	4	104	Tokushima	1	4
Miyagi	2	1,757	Gifu	2	13	Kagawa	1	13
Akita	1	131	Shizuoka	3	75	Ehime	3	13
Yamagata	3	355	Aichi	6	144	Kochi	2	8
Ibaraki	5	477	Mie	1	17	Fukuoka	4	56
Tochigi	9	542	Shiga	1	15	Saga	1	6
Gunma	2	154	Kyoto	3	49	Nagasaki	3	20
Saitama	4	443	Osaka	10	109	Kumamoto	1	19
Chiba	5	353	Hyogo	3	99	Oita	1	12
Tokyo	22	1,366	Nara	4	16	Miyazaki	1	12
Kanagawa	7	538	Wakayama	1	4	Kagoshima	2	6
Niigata	3	346	Tottori	1	2	Okinawa	1	22
Toyama	2	21	Shimane	1	11		-	
lshikawa	1	25	Okayama	3	35	Total	150	7,971

The number of participants examined at medical facilities outside Fukushima Prefecture.

	a. Number of	b. Those with finalized	Numb	er of participants	by grade (perso	ons)	Number of pa		Number of par	
	a. Number of participants	results		Percentages by	y grade (%)		nodules (	persons)	cysts (p	ersons)
	(persons)	(persons)	A		в	с	Percent	age (%)	Percenta	age (%)
		b/a (%)	A1	A2	в	C	≥5.1mm	≤5.0mm	≥20.1mm	≤20.0m
lunicipalities surve	yed in FY202		007	500	0	0	0	-		50
Kawamata	739	739	227	506	6	0	6	5	0	50
	_	100.0	30.7	68.5	0.8	0.0	0.8	0.7	0.0	68
Namie	954	954	298	640	16	0	16	5	0	64
		100.0	31.2	67.1	1.7	0.0	1.7	0.5	0.0	68
litate	346	346	104	232	10	0	10	1	0	
		100.0	30.1	67.1	2.9	0.0	2.9	0.3	0.0	69
Minamisoma	3,975	3,975	1,235	2,697	43	0	43	14	0	2,72
	-,	100.0	31.1	67.8	1.1	0.0	1.1	0.4	0.0	68
Date	4,039	4,039	1,159	2,847	33	0	33	23	0	2,8
Balo	1,000	100.0	28.7	70.5	0.8	0.0	0.8	0.6	0.0	70
Tamura	2,281	2,281	718	1,540	23	0	23	10	0	1,54
Tantara	2,201	100.0	31.5	67.5	1.0	0.0	1.0	0.4	0.0	67
Hiropo	289	289	93	191	5	0	5	1	0	19
Hirono	289	100.0	32.2	66.1	1.7	0.0	1.7	0.3	0.0	66
N1 1		369	114	253	2	0	2	1	0	2
Naraha	369	100.0	30.9	68.6	0.5	0.0	0.5	0.3	0.0	68
		715	212	497	6	0	6	4	0	5
Tomioka	715	100.0	29.7	69.5	0.8	0.0	0.8	0.6	0.0	70
		98	32	65	1	0.0	1	0.0	0.0	
Kawauchi	98	100.0	32.7	66.3	1.0	0.0	1.0	0.0	0.0	67
		670	196	464	1.0	0.0	1.0	9	0.0	4
Okuma	670	100.0	29.3	69.3	1.5	0.0	1.5	1.3	0.0	 69
		247	29.3	174	1.5	0.0	1.5	0	0.0	1
Futaba	247						·····			
		100.0	29.1	70.4	0.4	0.0	0.4	0.0	0.0	70
Katsurao	65	65	29	36	0	0	0	0	0	
		100.0	44.6	55.4	0.0	0.0	0.0	0.0	0.0	55
Fukushima	18,605	18,605	5,413	13,007	185	0	185	98	0	13,1
		100.0	29.1	69.9	1.0	0.0	1.0	0.5	0.0	70
Nihonmatsu	3,713	3,713	1,158	2,504	51	0	51	27	0	2,5
	-, -	100.0	31.2	67.4	1.4	0.0	1.4	0.7	0.0	68
Motomiya	2,211	2,211	668	1,522	21	0	21	9	0	1,5
motomju	_,	100.0	30.2	68.8	0.9	0.0	0.9	0.4	0.0	69
Otama	681	681	198	472	11	0	11	3	0	4
Otalila	001	100.0	29.1	69.3	1.6	0.0	1.6	0.4	0.0	70
Koriyama	20,620	20,620	5,589	14,805	226	0	226	128	0	14,9
Ronyama	20,020	100.0	27.1	71.8	1.1	0.0	1.1	0.6	0.0	72
Koori	789	789	245	535	9	0	9	2	0	5
NUUII	109	100.0	31.1	67.8	1.1	0.0	1.1	0.3	0.0	68
Kurdenst		559	181	371	7	0	7	2	0	3
Kunimi	559	100.0	32.4	66.4	1.3	0.0	1.3	0.4	0.0	67
<b>T</b>	000	332	88	239	5	0	5	0	1	2
Tenei	332	100.0	26.5	72.0	1.5	0.0	1.5	0.0	0.3	72
		4,240	1,201	2,993	46	0	46	25	0	3,0
Shirakawa	4,240	100.0	28.3	70.6	1.1	0.0	1.1	0.6	0.0	
		1,345	402	925	18	0.0	18	6	0.0	9
Nishigo	1,345	100.0	29.9	68.8	1.3	0.0	1.3	0.4	0.0	69
		394	119	271	4	0.0	4	2	0.0	2
Izumizaki	394	100.0	30.2	68.8	1.0	0.0	1.0	0.5	0.0	
										69
Miharu	903	903	248	646	9	0	9	6	0	
		100.0	27.5	71.5	1.0	0.0	1.0	0.7	0.0	72
Subtotal	69,179	69,179	19,999	48,432	748	0	748	381	1	48,8
	-, -	100.0	28.9	70.0	1.1	0.0	1.1	0.6	0.0	70

	a. Number of	b. Those with finalized	Numb	er of participants Percentages b		sons)	Number of pa nodules (	rticipants with persons)	Number of pa cysts (p	
	participants (persons)	results (persons) b/a (%)	A A1		B	С	Percent ≥5.1mm		Percent ≥20.1mm	
Municipalities surveye	ed in FY202	1								
Iwaki	18,581	18,581	5,309	13,017	255	0	255	107	0	13,154
		100.0 4,583	28.6 1,256	70.1 3,255	1.4 72	0.0	1.4 72	0.6 41	0.0	70.8 3,301
Sukagawa	4,583	100.0	27.4	71.0	1.6	0.0	1.6	0.9	0.0	72.0
Soma	1,781	1,781	523	1,227	31	0	31	12	0	1,245
	,	100.0 818	29.4 214	68.9 593	1.7 11	0.0	1.7 11	0.7	0.0	69.9 595
Kagamiishi	818	100.0	26.2	72.5	1.3	0.0	1.3	0.7	0.0	72.7
Shinchi	424	424	127	290	7	0	7	5	0	293
		100.0 266	30.0 78	68.4 187	1.7	0.0	1.7	1.2 2	0.0	69.1 188
Nakajima	266	100.0	29.3	70.3	0.4	0.0	0.4	0.8	0.0	70.7
Yabuki	978	978	279	694	5	0	5	4	0	697
i abaia	010	100.0	28.5	71.0	0.5	0.0	0.5	0.4	0.0	71.3
Ishikawa	790	790 100.0	226 28.6	557 70.5	7 0.9	0 0.0	7 0.9	5 0.6	0 0.0	561 71.0
Vomotouri	306	306	70	230	6	0	6	4	0.0	235
Yamatsuri	300	100.0	22.9	75.2	2.0	0.0	2.0	1.3	0.0	76.8
Asakawa	409	409 100.0	102 24.9	304 74.3	<u>3</u> 0.7	0.0	<u>3</u> 0.7	4	0.0	306 74.8
l line to	074	371	24.9	247	5	0.0	5	1.0	0.0	251
Hirata	371	100.0	32.1	66.6	1.3	0.0	1.3	0.3	0.0	67.7
Tanagura	847	847	224	611	12	0	12	2	0	618
		100.0 419	26.4 106	72.1	1.4 10	0.0	1.4 10	0.2	0.0	73.0 308
Hanawa	419	100.0	25.3	72.3	2.4	0.0	2.4	0.0	0.0	73.5
Samegawa	191	191	49	141	1	0	1	1	0	142
0		100.0 502	25.7 143	73.8	0.5	0.0	0.5	0.5	0.0	74.3 358
Ono	502	100.0	28.5	70.7	0.8	0.0	0.8	0.8	0.0	71.3
Tamagawa	386	386	125	256	5	0	5	1	0	260
ramagana		100.0	<u>32.4</u> 91	66.3	1.3	0.0	1.3	0.3	0.0	67.4
Furudono	337	337 100.0	27.0	241 71.5	5 1.5	0.0	5 1.5	0.9	0.0	245
Hinoemata	16	16	4	12	0	0.0	0	0.0	0.0	12
Timoerriata	10	100.0	25.0	75.0	0.0	0.0	0.0	0.0	0.0	75.0
Minamiaizu	666	666 100.0	205 30.8	453 68.0	8	0.0	8	2	0.0	459 68.9
Kanayama	20	38	12	26	0	0.0	0	0.0	0.0	26
Kaneyama	38	100.0	31.6	68.4	0.0	0.0	0.0	0.0	0.0	68.4
Showa	33	33 100.0	13 39.4	20 60.6	0.0	0 0.0	0.0	0.0	0.0	20 60.6
Min him n	45	45	8	36	1	0.0	1	0.0	0.0	37
Mishima	45	100.0	17.8	80.0	2.2	0.0	2.2	2.2	0.0	82.2
Shimogo	216	216 100.0	66	146 67.6	4	0 0.0	4 1.9	1 0.5	0.0	148 68.5
		2,227	30.6 692	1,509	1.9 26	0.0	26	10	0.0	1,525
Kitakata	2,227	100.0	31.1	67.8	1.2	0.0	1.2	0.4	0.0	68.5
Nishiaizu	201	201	44	154	3	0	3	3	0	155
		100.0 212	21.9 53	76.6 158	1.5 1	0.0	1.5 1	1.5 3	0.0	77.1 158
Tadami	212	100.0	25.0	74.5	0.5	0.0	0.5	1.4	0.0	74.5
Inawashiro	696	696	195	488	13	0	13	6	0	496
		100.0 159	28.0 44	70.1	1.9 1	0.0	1.9 1	0.9	0.0	71.3 114
Bandai	159	100.0	27.7	71.7	0.6	0.0	0.6	0.6	0.0	71.7
Kitashiobara	163	163	47	113	3	0	3	1	0	114
		100.0 987	28.8 297	69.3 681	1.8 9	0.0	1.8 9	0.6	0.0	69.9 686
Aizumisato	987	100.0	30.1	69.0	9 0.9	0.0	0.9	0.7	0.0	69.5
Aizubange	790	790	203	572	15	0	15	5	0	582
	, 50	100.0 148	25.7	72.4	1.9 1	0.0	1.9 1	0.6	0.0	73.7
Yanaizu	148	148	51 34.5	96 64.9	0.7	0.0	0.7	0.7	0.0	96 64.9
Aizuwakamatsu	5,983	5,983	1,799	4,113	71	0	71	39	0	4,155
	0,000	100.0	30.1	68.7	1.2	0.0	1.2	0.7	0.0	69.4
Yugawa	211	211 100.0	73 34.6	136 64.5	2 0.9	0.0	2 0.9	2 0.9	0.0	138 65.4
Subtatal	44 700	44,780	12,847	31,335	598	0.0	598	284	0.0	31,678
Subtotal	44,780	100.0	28.7	70.0	1.3	0.0	1.3	0.6	0.0	70.7
Total	113,959	113,959	32,846	79,767	1,346	0	1,346	665	1	80,526
	2,500	100.0	28.8	70.0	1.2	0.0	1.2	0.6	0.0	70.7


## Appendix 4-1: TUE primary examination results by age and gender

## As of December 31, 2024

(persons)

Grade/ Gender			ŀ	۱				в			с			Total	
Gender		A1			A2			0						Total	
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
8-11	3,862	3,338	7,200	8,951	8,852	17,803	21	43	64	0	0	0	12,834	12,233	25,067
12-17	10,583	9,052	19,635	25,072	25,227	50,299	251	487	738	0	0	0	35,906	34,766	70,672
18-24	2,807	3,204	6,011	5,382	6,283	11,665	159	385	544	0	0	0	8,348	9,872	18,220
Total	17,252	15,594	32,846	39,405	40,362	79,767	431	915	1,346	0	0	0	57,088	56,871	113,959

Results by age group (Male)




Results by age group (Female)



#### Appendix 4-2: Nodule characteristics

#### As of December 31, 2024


					(persons)
Nodule size	Total			Gra	do
	Total	Male	Female	0 a	ue
None	111,948	56,419	55,529	A1	98.2%
≤ 3.0mm	91	27	64	A2	0.6%
3.1–5.0mm	574	211	363	AZ	0.0%
5.1–10.0mm	862	284	578		
10.1–15.0mm	294	85	209		
15.1–20.0mm	114	42	72	В	1.2%
20.1–25.0mm	37	10	27		
≥ 25.1mm	39	10	29		
Total	113,959	57,088	56,871		





les □Nodules ≤ 5.0 mm


■Nodules ≥ 5.1 mm




#### Appendix 4 – 3: Cyst characteristics

#### As of December 31, 2024

					(persons)
Cyst size	Total -		Grad	10	
Cyst size	TOLAI	Male Female		Giac	
None	33,432	17,463	15,969	A1	68.1%
≤ 3.0mm	44,228	23,434	20,794		00.170
3.1–5.0mm	31,059	14,334	16,725		
5.1–10.0mm	5,119	1,829	3,290	A2	31.9%
10.1–15.0mm	106	25	81		31.9%
15.1–20.0mm	14	3	11		
20.1–25.0mm	0	0	0	D	0.0040/
≥ 25.1mm	1	0	1	В	0.001%
Total	113,959	57,088	56,871		





20

#### Appendix 5: Implementation status of the TUE confirmatory examination by area

#### As of December 31, 2024

	Those who participated in	Those refered to	Those who pa	rticipated in c	onfirmatory e	xamination		Those with f	inalized resu	ts (persons)	
	primary examination (persons)	examination examination	Total	8-11 years old	12-17 years old	18 and older	Total	A1	A2	Other thar	A1 or A2 FNAC
	a	b	с	d	е	f	g	h	i	j	k
		b/a (%)	Participation rate c/b (%)	d/c (%)	e/c (%)	f/c (%)	g/c (%)	h/g (%)	i/g (%)	j/g (%)	k/j (%)
13 municipalities 1)	14,787	156	129	8	62	59	126	0	12	114	8
13 municipanties 1)	14,767	1.1	82.7	6.2	48.1	45.7	97.7	0.0	9.5	90.5	7.0
Nakadari 2)	65 505	739	617	27	309	281	608	4	61	543	66
Nakadori 2)	65,595	1.1	83.5	4.4	50.1	45.5	98.5	0.7	10.0	89.3	12.2
Llamadari 2)	20,786	293	236	3	104	129	235	2	18	215	18
Hamadori 3)	20,700	1.4	80.5	1.3	44.1	54.7	99.6	0.9	7.7	91.5	8.4
A: A)	40.704	158	134	4	66	64	132	1	6	125	9
Aizu 4)	12,791	1.2	84.8	3.0	49.3	47.8	98.5	0.8	4.5	94.7	7.2
Tetel		1,346	1,116	42	541	533	1,101	7	97	997	101
Total 113,959	113,959	1.2	82.9	3.8	48.5	47.8	98.7	0.6	8.8	90.6	10.1

- 1) Tamura City, Minamisoma City, Date City, Kawamata Town, Hirono Town, Naraha Town, Tomioka Town, Kawauchi Village, Okuma Town, Futaba Town, Namie Town, Katsurao Village, Iitate Village
- 2) Fukushima City, Koriyama City, Shirakawa City, Sukagawa City, Nihonmatsu City, Motomiya City, Koori Town, Kunimi Town, Otama Village, Kagamiishi Town, Tenei Village, Nishigo Village, Izumizaki Village, Nakajima Village, Yabuki Town, Tanagura Town, Yamatsuri Town, Hanawa Town, Samegawa Village, Ishikawa Town, Tamakawa Village, Hirata Village, Asakawa Town, Furudono Town, Miharu Town, Ono Town
- 3) Iwaki City, Soma City, Shinchi Town
- 4) Aizuwakamatsu City, Kitakata City, Shimogo Town, Hinoemata Village, Tadami Town, Minamiaizu Town, Kitashiobara Village, Nishiaizu Town, Bandai Town, Inawashiro Town, Aizubange Town, Yugawa Village, Yanaizu Town, Mishima Town, Kaneyama Town, Showa Village, Aizumisato Town

Appendix 6: Surgery for cases malignant or suspicious for malignancy

1. Municipalities surveyed in FY2020 Malignant or suspicious for malignancy:	30 (surgical cases: 27, papillary thyroid carcinomas: 27)
2. Municipalities surveyed in FY2021 Malignant or suspicious for malignancy:	20 (surgical cases: 19, papillary thyroid carcinomas: 18, others: 1)
3. Total Malignant or suspicious for malignancy:	50 (surgical cases: 46, papillary thyroid carcinomas: 45, others: 1)

## Report on the TUE Full-Scale Survey (sixth-round survey)

As of December 31, 2024

#### 1. Summary

#### 1.1 Purpose

To monitor the long-term health of children, we are continuing the Full-Scale Survey (sixth-round survey), following the Preliminary Baseline Survey for initial assessment of thyroid glands, and prior Full-Scale Surveys (second, third, fourth, and fifth-round surveys) to continuously assess the status of thyroid glands.

#### 1.2 Eligible persons

All Fukushima residents who were approximately 18 years old or younger at the time of the earthquake (those born between April 2, 1992, and April 1, 2012).

#### **1.3 Implementation Period**

FY2023 and FY2024, starting in April 2023:

- 1.3-1 For those 18 years old or younger The examination was carried out for 2 years: FY2023 and FY2024.
- 1.3-2 For those 19 years old or older

The examination was conducted on an age-group basis (i.e., school grade). FY2023: those born between FY2000 and FY2003 FY2024: those born in FY2004

1.3-3 For those 25 years old or older

Those who are older than 20 are recommended to receive the examination every 5 years at the ages of 25, 30, and so on (Age 25 and Age 30 Surveys). FY2023: those born in FY1993 and FY1998 FY2024: those born in FY1994 and FY1999 Results of the survey for those 25 years old will be reported separately.

#### 1.4 Implementing Organizations (number of medical facilities with agreements for the implementation of thyroid examinations as of December 31, 2024)

Fukushima Prefecture commissioned Fukushima Medical University (FMU) to survey in cooperation with organizations inside and outside Fukushima for the convenience of participants.

1.4-1 Primary examination facilities	
In Fukushima Prefecture	85 medical facilities
Outside Fukushima Prefecture	150 medical facilities

1.4-2 Confirmatory examination facilities In Fukushima Prefecture 7 medical facilities, including FMU Outside Fukushima Prefecture 42 medical facilities

#### 1.5 Methods

1.5-1 Primary examination

Ultrasonography of the thyroid gland.

Assessments are made by specialists based on the following criteria:

- Grade A
  - A1: No nodules/cysts
  - A2: Nodules  $\leq$  5.0 mm or cysts  $\leq$  20.0 mm

- Grade B
- B: Nodules  $\geq$  5.1 mm or cysts  $\geq$  20.1 mm

Some A2 results may be re-classified as B results when clinically indicated.

-Grade C

C: Urgent need for confirmatory examination, judging from the condition of the thyroid gland.

1.5-2 Confirmatory examination

Ultrasonography of the thyroid gland, blood and urine tests, and fine needle aspiration cytology (FNAC) if needed for those with B or C test results.

Priority is given to those in urgent clinical need. A medical follow-up may be recommended based on confirmatory exam results.

1.5-3 Flow chart




Figure 1: Flow chart

#### **1.6 Municipalities Surveyed**

The municipalities where examinations (for those 18 years old or younger) were carried out in FY2023 and FY2024 are as follows:




Figure 2: Municipalities covered for primary examinations in FY2023 and FY2024

## 2. Results as of December 31, 2024

## 2.1 Results of the Primary Examination

2.1-1 Implementation status

The primary examination was completed for 63,705 participants (30.1%) by December 31, 2024. (Refer to Appendix 1 for the status by municipalities in Fukushima, and Appendix 2 for by prefectures outside Fukushima.)

The results of 59,381 (93.2%) examinees have been finalized, and individual reports have been sent to them. (Refer to Appendix 3 for the primary examination results by the municipality.)

Of these, 15,963 (26.9%) had Grade A1 results, 42,534 (71.6%) had Grade A2, 884 (1.5%) had Grade B, and none had Grade C.

		Participants (	persons)				Participants with finalized results (persons)							
	Eligible						Details by grade (%)							
	persons		Participation rate (%)			Judgment rate (%)	A		Α		Those referred exa		to confirmatory	
				Fukushima			A	1	A	2	В		C	;
	а	b	(b/a)		С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/c)
FY2023	121,814	41,147	(33.8)	3,070	40,781	(99.1)	10,981	(26.9)	29,249	(71.7)	551	(1.4)	0	(0.0)
FY2024	90,098	22,558	(25.0)	1,296	18,600	(82.5)	4,982	(26.8)	13,285	(71.4)	333	(1.8)	0	(0.0)
Total	211,912	63,705	(30.1)	4,366	59,381	(93.2)	15,963	(26.9)	42,534	(71.6)	884	(1.5)	0	(0.0)

Table 1: Progress and results of the primary examination

Table 2: Number and proportion of participants with nodules/cysts. (See Appendix 4 for details)

				Partici	oants with	nodules / cyst	s (%)				
	Participants with finalized results		Nodules				Cysts				
	initialized results	≥ 5.1n	≥ 5.1mm		≤ 5.0mm		mm	≤ 20.0mm			
	а	b	(b/a)	с	(c/a)	d	(d/a)	е	(e/a)		
FY2023	40,781	547	(1.3)	270	(0.7)	4	(0.0)	29,570	(72.5)		
FY2024	18,600	331	(1.8)	148	(0.8)	2	(0.0)	13,469	(72.4)		
Total	59,381	878	(1.5)	418	(0.7)	6	(0.0)	43,039	(72.5)		

- Proportions are rounded to a lower decimal place. This applies to other tables as well.
- Those who receive the examination at 5-year intervals (born between FY1992 and FY1999) are excluded. The results of examinations at 5-year intervals (Age 25 and Age 30 Surveys) will be reported separately.
- Examinations for those born in FY1993 (approx. 22,000) and FY1998 (approx. 21,000) took place in FY2023. Examinations for those born in FY1994 (approx. 22,000) and FY1999 (approx. 20,000) were carried out in FY2024.

#### 2.1-2 Participation rate by age group

Table 3 shows the participation rate for each age group as of April 1 of each fiscal year.

			Total		Age group	
	Age group*			11 years old	12 to 17 years old	18 to 24 years old
FY2023	Eligible persons	(a)	121,814	8,420	58,639	54,755
	Participants	(b)	41,147	5,048	32,815	3,284
	Participation rate (%)	(b/a)	33.8	60.0	56.0	6.0
	Age group*				12 to 17 years old	18 to 24 years old
FY2024	Eligible persons	(a)	90,098		41,660	48,438
	Participants	(b)	22,558		19,037	3,521
	Participation rate (%)	(b/a)	25.0		45.7	7.3
	Eligible persons	(a)	211,912	8,420	100,299	103,193
Total	Participants	(b)	63,705	5,048	51,852	6,805
	Participation rate (%)	(b/a)	30.1	60.0	51.7	6.6

Table 3: Participation rates by age group

\* Age groups are based on ages as of April 1 of each fiscal year

2.1-3 Comparison of the fifth- and sixth-round survey results

Table 4 shows the comparison of results of the two Full-Scale Surveys (fifth- and sixth-round surveys).

Among 53,023 (sum of \*1) participants with Grade A1 and A2 results in the fifth-round survey, 52,612 (sum of \*2, 99.2%) had Grade A results, and 411 (sum of \*3, 0.8%) had Grade B results in the sixth-round survey.

Among 461 participants with Grade B results in the fifth-round survey, 98 (sum of \*4, 21.3%) had Grade A results, and 363 (78.7%) had Grade B results in the sixth-round survey.

			Results of the	Res	ults of the sixth-	round survey**	
			fifth-round	A	A	В	с
			survey*	A1	A2	Б	U
			а	b	с	d	е
			(%)	(b/a)	(c/a)	(d/a)	(e/a)
	А	A1	14,569 *1	10,472 *2	4,027 *2	70 *3	0
			(100.0)	(71.9)	(27.6)	(0.5)	(0.0)
		A2	38,454 *1	3,764 *2	34,349 *2	341 *3	0
Results of			(100.0)	(9.8)	(89.3)	(0.9)	(0.0)
the fifth-round	В		461	10 *4	88 *4	363	0
survey		В	(100.0)	(2.2)	(19.1)	(78.7)	(0.0)
Survey		С	0	0	0	0	0
		C	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	Did n	ot participate	5,897	1,717	4,070	110	0
		or participate	(100.0)	(29.1)	(69.0)	(1.9)	(0.0)
т	Total		59,381	15,963	42,534	884	0
I	Total			(26.9)	(71.6)	(1.5)	(0.0)

Table 4: Comparison of the fifth- and sixth-round surveys

\* Results of the fifth-round survey are from sixth-round survey participants with finalized results, not the breakdown of all fifth-round survey participants.

\*\* Results of the sixth-round survey participants who were diagnosed for each grade in the fifth-round survey.

## 2.2 Results of the Confirmatory Examination

#### 2.2-1 Implementation status

By December 31, 2024, of 884 eligible persons, 555 (62.8%) had participated in the confirmatory examination, and 493 (88.8%) had completed the entire procedure.

Of those 493 participants, 38 (A1: 1, A2: 37) (7.7%) were confirmed to meet A1 or A2 diagnostic criteria by primary examination standards (including those with other thyroid conditions). After the detailed examination, 455 (92.3%) were confirmed to be outside the A1 or A2 criteria.

	Those		cipants		Those with finalized results (persons)									
	referred to confirmatory	(pei	(persons) Participation		Determination		A1		A2		ther than	A1 or A2		
	exams		Rate (%)	rate (%)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		~~ <b>~</b>				FNAC		
	а	b	(b/a)	С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/f)	
FY2023	551	411	(74.6)	378	(92.0)	1	(0.3)	29	(7.7)	348	(92.1)	23	(6.6)	
FY2024	333	144	(43.2)	115	(79.9)	0	(0.0)	8	(7.0)	107	(93.0)	7	(6.5)	
Total	884	555	(62.8)	493	(88.8)	1	(0.2)	37	(7.5)	455	(92.3)	30	(6.6)	

Table 5: Progress and results of the confirmatory examination

2.2-2 Results of fine needle aspiration cytology (FNAC)

Among those who underwent FNAC, 14 participants were diagnosed with lesions malignant or suspicious for malignancy: 4 were male and 10 were female. Participants' ages at the confirmatory examination ranged from 12 to 21 years (mean age:  $17.6 \pm 2.8$  years). The tumor diameters were from 8.2 mm to 18.6 mm (mean tumor diameter:  $13.0 \pm 3.1$  mm).


Of these 14 participants, 7 had Grade A (A1:2, A2:5), 3 had Grade B results in the fifth-round survey, and the remaining 4 did not participate. Among 5 participants with Grade A2, 4 met nodule criteria, and 1 met both cyst and nodule criteria.

Table 6: Results of FNAC (The mean age and mean tumor size in parentheses indicate the range.)

Those referred to confirmatory examination <ul> <li>Malignant or suspicious for malignancy.</li> </ul>	-
Male to female ratio:	4:10
• Mean age ± SD (min-max)	
• Mean age ± SD (min-max)	$17.6 \pm 2.8 (12-21)$
	$4.6 \pm 2.8 (0-9)$ at the time of the earthquake
<ul> <li>Mean tumor size ± SD (min-max)</li> </ul>	13.0 ± 3.1 mm (8.2–18.6 mm)

\*Refer to Appendix 5 for surgical cases

2.2-3 Age distribution of malignant or suspected malignant cases diagnosed by FNAC Figure 4 shows the age distribution of 14 people with malignant or suspected malignant nodules based on their age as of March 11, 2011. The age distribution based on their age at the time of confirmatory examination is in Figure 5.



Note: Those aged between 11 and 18 at the time of the disaster are not included in the sixth-round survey participants.

The horizontal axis begins at -1, including those born between April 2, 2011, and April 1, 2012.

\*Those born between March 12 and April 1, 2011, are included in age 0.




Figure 4: Age distributions as of March 11, 2011

Figure 5: Age distributions as of the date of confirmatory examination

2.2-4 Basic Survey results for those deemed malignant or suspicious for malignancy by FNAC Of those 14 people with malignant or suspicious findings, 11 (78.6%) had participated in the Basic Survey (for external radiation exposure dose estimation), and all 11 received their results. The highest effective dose documented was 1.9 mSv.

Effective		Age at the time of the earthquake											
dose	0–5		6–10		11–15		16-	-18	Total				
(mSv)	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female			
< 1	1	2	0	2	0	0	0	0	1	4			
< 2	2	2	0	2	0	0	0	0	2	4			
< 5	0	0	0	0	0	0	0	0	0	0			
< 10	0	0	0	0	0	0	0	0	0	0			
< 20	0	0	0	0	0	0	0	0	0	0			
≥ 20	0	0	0	0	0	0	0	0	0	0			
Total	3	4	0	4	0	0	0	0	3	8			

Table 7: A breakdown of dose estimates for Basic Survey participants




Figure 6: Effective dose distribution of the Basic Survey participants

#### 2.2-5 Blood test and urinary iodine test results

	FT4 <sup>1</sup> (ng/dl		FT3 <sup>2)</sup> (pg/mL)	TSH <sup>3</sup> (µIU/m		Tg <sup>4)</sup> (ng/mL)	TgAb <sup>5)</sup> (IU/mL)	TPOAb <sup>6)</sup> (IU/mL)
Reference Range	0.95–1.74 <sup>7)</sup>		2.13-4.077)	0.340-3.880 <sup>7)</sup>		≤ 33.7	< 28.0	< 16.0
Malignant or suspicious : 14	1.2±0.2 (7.1%)		3.5±0.6 (21.4%)	1.4±0.6 (0.0%)		34.5±34.6 (42.9%)	14.3%	21.4%
Other : 415	1.2±0.2	(4.6%)	3.6±0.5 (8.9%)	1.3±1.3	(9.9%)	31.1±159.2 (13.0%)	7.2%	8.9%

#### Table 8: Blood test results

Table 9: Urinary iodine test results <sup>8)</sup>

						(µg/day)
		Minimum	25th percentile	Median	75th percentile	Maximum
Malignant or . suspicious	10	88	135	285	476	757
Other :	166	39	115	188	375	5,521

- 1) FT4: free thyroxine, thyroid hormone binding 4 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).
- 2) FT3: free triiodothyronine, thyroid hormone binding 3 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).
- TSH: thyroid-stimulating hormone; higher among patients with Hashimoto's disease and lower with Graves' disease.
- 4) Tg: thyroglobulin; higher when thyroid tissue is destroyed or when neoplastic tissue produces thyroglobulin.
- 5) TgAb: anti-thyroglobulin antibody; higher among patients with Hashimoto's disease or Graves' disease.
- 6) TPOAb: anti-thyroid peroxidase antibody; higher among patients with Hashimoto's disease or Graves' disease.
- 7) Reference intervals vary according to age.
- 8) Due to the temporary suspension of reagents, the urinary iodine tests have been suspended since March 8, 2024, as of December 31, 2024.

#### 3. Mental Health Care

We provide the following support for thyroid examination participants.

#### 3.1 Support for Primary Examination Participants

After the examination, medical doctors offer person-to-person explanations of examination results, showing ultrasound images in private consultation booths at examination venues set up in public facilities.

Consultation booths were set up at all venues for examinations conducted in and after April 2023; as of December 31, 2024, all 1,273 participants (100%) have visited these consultation booths.

#### 3.2 Outreach programs (on-location lectures and information sessions)

To help participants and their parents/guardians improve their understanding of the thyroid examination, we have conducted on-location lectures and information sessions.

Between April 2023 (the start of FY2023) and December 31, 2024, we delivered 13 on-location sessions (5 at elementary schools, 6 at junior high schools, and 2 at high schools) for 1,257 students. In total, 16,950 people have participated since the start of these sessions.

#### 3.3 Support for Confirmatory Examination Participants

A support team has been established within Fukushima Medical University to offer mental health support to those undergoing the confirmatory (secondary) examination to address their concerns and anxiety, as well as to answer questions and provide guidance via web consultation.

Since the start of the sixth-round survey, 230 participants (82 males and 148 females) have received support as of December 31, 2024. The number of support sessions, including telephone counseling, was 353 in total. Of these, 230 (65.2%) received support at the participants' first examination and 123 (34.8%) at subsequent examinations.

For those who proceeded to regular insured medical care, the support team continues to provide support in cooperation with teams of medical staff at hospitals.

Appendix 1: Implementation status of the TUE primary examination by municipality

#### As of December 31, 2024

	Number of eligible persons	Participants (persons)	Participated	Participation rate(%)		rticipants and rate by age group <sup>2)</sup>	participation	Participants living outside Fukushima	%
	а	b	outside Fukushima <sup>1)</sup>	b/a	11	12–17	18–24	c <sup>3)</sup>	c/b
Municipalities surve	yed in FY202	3	11		II			L1	
Kawamata	1,282	400	10	31.2	29	331	40	13	3.3
Nawamala	1,202	400	10	31.2	7.3	82.8	10.0	15	3.3
Namie	2,063	489	98	23.7	29	339	121	109	22.3
	2,000			20	5.9	69.3	24.7		22.0
litate	620	184	6	29.7	10 5.4	142 77.2	32 17.4	6	3.3
					163	1,542	339		
Minamisoma	7,561	2,044	301	27.0	8.0	75.4	16.6	322	15.8
Data	0.000	0.040	00	20.0	201	1,790	325	04	2.0
Date	6,096	2,316	90	38.0	8.7	77.3	14.0	91	3.9
Tamura	3,783	1,299	34	34.3	108	1,023	168	29	2.2
ranara	0,100	1,200		01.0	8.3	78.8	12.9		2.2
Hirono	538	141	10	26.2	10	99	32	11	7.8
					7.1	70.2	22.7		
Naraha	766	151	17	19.7	4	99 65.6	48 31.8	19	12.6
					2.0	226	<u> </u>		
Tomioka	1,640	342	58	20.9	5.0	66.1	28.9	52	15.2
					1	37	14		
Kawauchi	192	52	2	27.1	1.9	71.2	26.9	3	5.8
Okuma	1 501	351	68	23.1	14	244	93	70	10.0
Okuma	1,521	351	00	23.1	4.0	69.5	26.5	70	19.9
Futaba	717	117	17	16.3	4	84	29	17	14.5
T diaba	, . ,	117		10.0	3.4	71.8	24.8		14.0
Katsurao	126	31	2	24.6	3	19	9	3	9.7
					9.7	61.3 8,979	29.0		
Fukushima	31,363	11,121	828	35.5	666 6.0	8,979 80.7	<u>1,476</u> 13.3	822	7.4
					167	1,686	226		
Nihonmatsu	5,779	2,079	95	36.0	8.0	81.1	10.9	99	4.8
	0.500	4.050	40	05.4	105	977	168		0.0
Motomiya	3,566	1,250	46	35.1	8.4	78.2	13.4	41	3.3
Otama	951	403	5	42.4	28	321	54	6	1.5
Otalilla	901	403	5	42.4	6.9	79.7	13.4	0	1.5
Koriyama	38,693	13,190	1,144	34.1	282	10,885	2,023	1,106	8.4
litonyama			.,	• …	2.1	82.5	15.3	.,	0
Koori	1,139	480	20	42.1	48	354	78	22	4.6
	-				10.0	73.8	16.3		
Kunimi	827	292	11	35.3	16	226	50	9	3.1
					5.5 9	77.4 155	17.1 30	-	
Tenei	621	194	7	31.2	4.6	79.9	15.5	6	3.1
					120	2,118	389		
Shirakawa	7,161	2,627	140	36.7	4.6	80.6	14.8	127	4.8
					36	692	113	_	-
Nishigo	2,410	841	40	34.9	4.3	82.3	13.4	34	4.0
laumiaeki	750	000		20.0	7	189	26	_	0.0
Izumizaki	759	222	4	29.2	3.2	85.1	11.7	2	0.9
Miharu	1,640	531	17	32.4	18	433	80	17	3.2
i i i i i i i i i i i i i i i i i i i	1,040	001		02.4	3.4	81.5	15.1		0.2
Subtotal	121,814	41,147	3,070	33.8	2,095	32,990	6,062	3,036	7.4
	,-	, .	.,		5.1	80.2	14.7	,	

\*1) The number of participants who received the examination at facilities outside Fukushima (as of November 30, 2024).

\*2) Split cells show the number of participants above the corresponding percentage.

\*3) The number of participants who have resident registration outside Fukushima.

•Age groups are based on participants' age at the Full-Scale Survey (sixth-round survey). This applies to other tables hereafter.

## 55\_2-2\_TUE(EN)\_Report on the TUE Full-Scale Survey (6th-round\_ survey)

	Number of eligible persons	Participants (persons)	Participated outside	Participation rate(%)		articipants and rate by age group <sup>2)</sup>	participation	Participants living outside Fukushima	%
	а	b	Fukushima <sup>1)</sup>	b/a	11	12–17	18–24	c <sup>3)</sup>	c/b
Municipalities surve	yed in FY202	4							
Iwaki	35,474	6,900	689	19.5	18 0.3	4,402 63.8	2,480 35.9	594	8.6
Sukagawa	8,982	2,781	110	31.0	7 0.3	2,254 81.0	520 18.7	87	3.1
Soma	4,020	983	92	24.5	9 0.9	794 80.8	180 18.3	91	9.3
Kagamiishi	1,550	493	14	31.8	0 0.0	409 83.0	84 17.0	13	2.6
Shinchi	827	247	16	29.9	1 0.4	182 73.7	64 25.9	15	6.1
Nakajima	586	150	0	25.6	0 0.0	134 89.3	16 10.7	1	0.7
Yabuki	1,975	605	18	30.6	2 0.3	499 82.5	104 17.2	12	2.0
Ishikawa	1,535	480	10	31.3	2 0.4	406 84.6	72 15.0	10	2.1
Yamatsuri	564	194	11	34.4	0 0.0	162 83.5	32 16.5	5	2.6
Asakawa	768	228	11	29.7	0 0.0	184 80.7	44 19.3	9	3.9
Hirata	692	224	5	32.4	0 0.0	191 85.3	33 14.7	4	1.8
Tanagura	1,707	533	18	31.2	2 0.4	452 84.8	79 14.8	10	1.9
Hanawa	866	246	13	28.4	1 0.4	204 82.9	41 16.7	7	2.8
Samegawa	385	118	1	30.6	1 0.8	105 89.0	12 10.2	2	1.7
Ono	1,044	301	6	28.8	1 0.3	255 84.7	45 15.0	4	1.3
Tamakawa	774	207	6	26.7	1 0.5	166 80.2	40 19.3	0	0.0
Furudono	571	207	7	36.3	0 0.0	164 79.2	43 20.8	4	1.9
Hinoemata	58	5	0	8.6	0 0.0	5 100.0	0 0.0	0	0.0
Minamiaizu	1,483	364	9	24.5	0 0.0	323 88.7	41 11.3	6	1.6
Kaneyama	90	26	0	28.9	0 0.0	21 80.8	5 19.2	0	0.0
Showa	89	22	1	24.7	0 0.0	20 90.9	2 9.1	1	4.5
Mishima	106	27	0	25.5	0 0.0	21 77.8	6 22.2	0	0.0
Shimogo	527	114	2	21.6	0 0.0	101 88.6	13 11.4	3	2.6
Kitakata	4,942	1,362	34	27.6	2 0.1	1,164 85.5	196 14.4	28	2.1
Nishiaizu	491	127	5	25.9	0 0.0	109 85.8	18 14.2	3	2.4
Tadami	401	117	3	29.2	1 0.9	102 87.2	14 12.0	3	2.6
Inawashiro	1,467	425	16	29.0	1 0.2	355 83.5	69 16.2	13	3.1
Bandai	357	110	5	30.8	0 0.0	88 80.0	22 20.0	6	5.5
Kitashiobara	324	105	2	32.4	0 0.0	92 87.6	13 12.4	3	2.9
Aizumisato	1,953	566	11	29.0	0 0.0	471 83.2	95 16.8	8	1.4
Aizubange	1,671	464	12	27.8	2 0.4	386 83.2	76 16.4	9	1.9
Yanaizu	326	87	0	26.7	0 0.0	81 93.1	6.9	0	0.0
Aizuwakamatsu	13,118	3,613	167	27.5	8 0.2	2,945 81.5	660 18.3	148	4.1
Yugawa	375	127	2	33.9	0 0.0	97 76.4	30 23.6	3	2.4
Subtotal	90,098	22,558	1,296	25.0	59 0.3	<u>17,344</u> 76.9	5,155 22.9	1,102	4.9
Total	211,912	63,705	4,366	30.1	2,154 3.4	50,334 79.0	<u>11,217</u> 17.6	4,138	6.5

Appendix 2: Implementation status of the TUE primary examination by prefecture

As of November 30, 2024

Prefecture	Number of medical facilities	Participants (persons)	Prefecture	Number of medical facilities	Participants (persons)	Prefecture	Number of medical facilities	Participants (persons)
Hokkaido	7	111	Fukui	1	11	Hiroshima	2	13
Aomori	3	56	Yamanashi	2	33	Yamaguchi	1	5
lwate	4	98	Nagano	4	63	Tokushima	1	5
Miyagi	2	1,052	Gifu	2	16	Kagawa	1	6
Akita	1	77	Shizuoka	3	44	Ehime	3	11
Yamagata	3	171	Aichi	6	84	Kochi	2	8
Ibaraki	5	235	Mie	1	9	Fukuoka	4	26
Tochigi	9	324	Shiga	1	7	Saga	1	2
Gunma	2	67	Kyoto	3	20	Nagasaki	3	12
Saitama	4	231	Osaka	10	59	Kumamoto	1	11
Chiba	5	123	Hyogo	3	53	Oita	1	13
Tokyo	22	778	Nara	4	12	Miyazaki	1	9
Kanagawa	7	287	Wakayama	1	2	Kagoshima	2	3
Niigata	3	162	Tottori	1	0	Okinawa	1	13
Toyama	2	10	Shimane	1	4			
lshikawa	1	5	Okayama	3	25	Total	150	4,366

The number of participants examined at medical facilities outside Fukushima Prefecture.

## Appendix 3: TUE primary examination results by the municipality

## As of December 31, 2024

		b. Those with	Number of participants by grade (persons)					rticipants with	Number of participants with		
	a. Number of participants (persons)	finalized results (persons)		Percentages	by grade (%)		nodules	persons)	cysts (p	ersons)	
	(poroono)	b/a (%)	A1	A A2	В	С	Percent ≥5.1mm	age (%) ≤5.0mm	Percent ≥20.1mm	age (%) ≤20.0m	
<i>Aunicipalities surve</i>	yed in FY202		1	1	_ 1		_	-			
Kawamata	400	400	95	298	7	0	7	3	0	303	
		100.0	23.8	74.5	1.8	0.0	1.8	0.8	0.0	75.8	
Namie	489	456 93.3	126 27.6	<u>324</u> 71.1	6 1.3	0.0	<u>5</u>	<u>8</u> 1.8	<u>1</u>	324 71.1	
		182	45	134	3	0.0	3	0	0.2	137	
litate	184	98.9	24.7	73.6	1.6	0.0	1.6	0.0	0.0	75.3	
N 4i i	0.044	2,025	523	1,469	33	0	33	12	0	1,490	
Minamisoma	2,044	99.1	25.8	72.5	1.6	0.0	1.6	0.6	0.0	73.6	
Date	2,316	2,314	579	1,707	28	0	28	21	0	1,722	
Dale	2,510	99.9	25.0	73.8	1.2	0.0	1.2	0.9	0.0	74.4	
Tamura	Tamura 1,299	1,296	362	919	15	0	15	8	0	927	
ramara	1,200	99.8	27.9	70.9	1.2	0.0	1.2	0.6	0.0	71.5	
Hirono	141	121	42	75	4	0	4	1	0	77	
		85.8	34.7	62.0	3.3	0.0	3.3	0.8	0.0	63.6	
Naraha	151	121	35	84	2	0	2	1	0	84	
		80.1	28.9	69.4	1.7	0.0	1.7	0.8	0.0	69.4	
Tomioka	342	298 87.1	78 26.2	217 72.8	<u> </u>	0.0	3	4	0	220 73.8	
		87.1 50	26.2	33		0.0	1.0		0.0		
Kawauchi	52	96.2	32.0	66.0	1 2.0	0.0	2.0	0.0	0.0	34 68.0	
		301	92	204	2.0	0.0	2.0	3	0.0	205	
Okuma	351	85.8	30.6	67.8	1.7	0.0	1.7	1.0	0.0	68.1	
		105	28	77	0	0.0	0	1.0	0.0	76	
Futaba 117	89.7	26.7	73.3	0.0	0.0	0.0	1.0	0.0	72.4		
	-	31	6	25	0	0	0	0	0	25	
Katsurao	31	100.0	19.4	80.6	0.0	0.0	0.0	0.0	0.0	80.6	
<b>Ful</b> rushimes	11 101	11,065	3,035	7,885	145	0	143	63	2	7,965	
Fukushima	11,121	99.5	27.4	71.3	1.3	0.0	1.3	0.6	0.0	72.0	
Nihonmatsu	2,079	2,071	627	1,416	28	0	28	9	0	1,438	
Ninonmatsu	2,013	99.6	30.3	68.4	1.4	0.0	1.4	0.4	0.0	69.4	
Motomiya	1,250	1,246	354	878	14	0	14	6	0	886	
meteringu	.,200	99.7	28.4	70.5	1.1	0.0	1.1	0.5	0.0	71.1	
Otama	403	402	112	279	11	0	11	2	0	285	
		99.8	27.9	69.4	2.7	0.0	2.7	0.5	0.0	70.9	
Koriyama	13,190	13,130	3,475	9,478	177	0	176	81	1	9,591	
		99.5	26.5	72.2	1.3 8	0.0	1.3	0.6	0.0	73.0	
Koori	480	480 100.0	133 27.7	339 70.6	0 1.7	0.0	8	4	0.0	344 71.7	
		291	90	191	1.7	0.0	1.7	2	0.0	197	
Kunimi	292	99.7	30.9	65.6	3.4	0.0	3.4	0.7	0.0	67.7	
		193	44	147	2	0.0	2	2	0.0	148	
Tenei	194	99.5	22.8	76.2	1.0	0.0	1.0	1.0	0.0	76.7	
		2,614	654	1,928	32	0	32	22	0	1,940	
Shirakawa	2,627	99.5	25.0	73.8	1.2	0.0	1.2	0.8	0.0	74.2	
NP 11		840	232	598	10	0	10	9	0	605	
Nishigo	841	99.9	27.6	71.2	1.2	0.0	1.2	1.1	0.0	72.0	
	000	220	62	155	3	0	3	2	0	157	
Izumizaki	222	99.1	28.2	70.5	1.4	0.0	1.4	0.9	0.0	71.4	
Miboru	E04	529	136	389	4	0	4	6	0	390	
Miharu	531	99.6	25.7	73.5	0.8	0.0	0.8	1.1	0.0	73.7	
Subtotal	41,147	40,781	10,981	29,249	551	0	547	270	4	29,570	
Gustolai		99.1	26.9	71.7	1.4	0.0	1.3	0.7	0.0	72.5	

## 55\_2-2\_TUE(EN)\_Report on the TUE Full-Scale Survey (6th-round\_ survey)


	a. Number of participants	b. Those with finalized results	Numb	er of participant		sons)	Number of pa nodules	rticipants with (persons)	Number of participants with cysts (persons)		
	(persons)	(persons) - b/a (%)	A1	A2	В	С	Percent ≥5.1mm	age (%) ≤5.0mm	Percenta ≥20.1mm	age (%) ≤20.0m	
inicipalities survey	ed in FY202										
Iwaki	6,900	4,847	1,400	3,334	113	0	113	35	0	3,39	
		70.2 2,760	28.9 725	68.8 1,982	2.3 53	0.0	2.3 53	0.7	0.0	70. 2,01	
Sukagawa	2,781	99.2	26.3	71.8	1.9	0.0	1.9	0.6	0.0	73.	
Soma	983	975	256	701	18	0	18	12	0	71	
Soma	903	99.2	26.3	71.9	1.8	0.0	1.8	1.2	0.0	72.	
Kagamiishi	493	491	120	367	4	0	4	0	0	37	
		99.6 245	24.4	74.7	0.8	0.0	0.8	0.0	0.0	75. 17	
Shinchi	247	99.2	26.9	70.2	2.9	0.0	2.9	0.8	0.0		
Nakajima	150	150	43	107	0	0	0	1	0	10	
Nakajima	150	100.0	28.7	71.3	0.0	0.0	0.0	0.7	0.0	71.	
Yabuki	605	604	168	427	9	0	9	3	0	43	
		99.8	27.8	70.7	1.5	0.0	1.5	0.5	0.0	71.	
Ishikawa	480	473 98.5	115 24.3	348 73.6	10 2.1	0.0	9 1.9	6 1.3	0.2	35 74.	
		192	45	146	1	0.0	1.0	4	0.2	14	
Yamatsuri	194	99.0	23.4	76.0	0.5	0.0	0.5	2.1	0.0	76	
Asakawa	228	228	60	165	3	0	3	1	0	16	
Asakawa	220	100.0	26.3	72.4	1.3	0.0	1.3	0.4	0.0	73	
Hirata	224	222	52	165	5	0	5	3	0	16	
		99.1	23.4	74.3	2.3	0.0	2.3	1.4	0.0	76	
Tanagura	533	530 99.4	133 25.1	389 73.4	8 1.5	0.0	8	4 0.8	0.0	39 74	
		245	71	172	2	0.0	2	5	0.0	17	
Hanawa	246	99.6	29.0	70.2	0.8	0.0	0.8	2.0	0.0	70	
Samegawa	118	118	37	79	2	0	2	1	0	8	
Sameyawa	110	100.0	31.4	66.9	1.7	0.0	1.7	0.8	0.0	68	
Ono	301	300	74	220	6	0	6	2	0	22	
-		99.7	24.7	73.3	2.0	0.0	2.0	0.7	0.0	74	
Tamakawa	207	202 97.6	59 29.2	139 68.8	4	0.0	4	<u>2</u> 1.0	0.0	14 69	
		204	<u>29.2</u> 53	147	2.0	0.0	2.0	1.0	0.0	15	
Furudono	207	98.6	26.0	72.1	2.0	0.0	2.0	0.5	0.0	73	
Hinoemata	5	5	2	3	0	0	0	1	0		
Hinoemala	5	100.0	40.0	60.0	0.0	0.0	0.0	20.0	0.0	60	
Minamiaizu	364	322	84	233	5	0	5	3	0	23	
		88.5	26.1	72.4	1.6	0.0	1.6	0.9	0.0	73	
Kaneyama	26	24 92.3	7 29.2	17 70.8	0.0	0.0	0.0	0.0	0.0	70	
		92.3	29.2	12	0.0	0.0	0.0	0.0	0.0	10	
Showa	22	90.9	40.0	60.0	0.0	0.0	0.0	0.0	0.0	60	
Mishima	27	24	3	21	0	0	0	0	0	2	
WISTIITIA	21	88.9	12.5	87.5	0.0	0.0	0.0	0.0	0.0	87	
Shimogo	114	105	25	79	1	0	1	1	0		
5		92.1	23.8	75.2	1.0	0.0	1.0	1.0	0.0	74	
Kitakata	1,362	951 69.8	242	695 73 1	<u>14</u> 1.5	0.0	14 1.5	<u>13</u> 1.4	0 0.0	69 73	
		114	25.4 17	73.1 95	1.5	0.0	1.5	0	0.0	73	
Nishiaizu	127	89.8	14.9	83.3	1.8	0.0	1.8	0.0	0.0	85	
Tadami	117	112	21	88	3	0	3	2	0	8	
raudillí	11/	95.7	18.8	78.6	2.7	0.0	2.7	1.8	0.0	79	
Inawashiro	425	389	121	262	6	0	5	1	1	20	
		91.5	31.1	67.4	1.5	0.0	1.3	0.3	0.3	67	
Bandai	110	86 78.2	24 27.9	61 70.9	<u>1</u> 1.2	0.0	1 1.2	<u>1</u> 1.2	0.0	70	
		98	27.9	70.9	1.2	0.0	1.2	1.2	0.0	70	
Kitashiobara	105	93.3	20.4	78.6	1.0	0.0	1.0	1.0	0.0	78	
Aizumisato	566	479	134	341	4	0	4	5	0	34	
	500	84.6	28.0	71.2	0.8	0.0	0.8	1.0	0.0	71	
Aizubange	464	407	106	291	10	0	10	6	0	2	
		87.7 80	26.0 24	71.5 56	2.5 0	0.0	2.5 0	1.5 0	0.0	73	
Yanaizu	87	92.0	30.0	70.0	0.0	0.0	0.0	0.0	0.0	70	
		2,491	633	1,826	32	0.0	32	16	0.0	1,8	
Aizuwakamatsu	3,613	68.9	25.4	73.3	1.3	0.0	1.3	0.6	0.0	74	
Yugawa	127	107	34	68	5	0	5	0	0		
ruyawa	127	84.3	31.8	63.6	4.7	0.0	4.7	0.0	0.0	68	
Subtotal	22,558	18,600	4,982	13,285	333	0	331	148	2	13,4	
	,000	82.5	26.8	71.4	1.8	0.0	1.8	0.8	0.0	72	
		59,381	15,963	42,534	884	0	878	418	6	43,0	


Appendix 4-1: TUE examination results by age and gender

#### As of December 31, 2024

															(persons)
Result Gender			A	4				в		с			Total		
Gender		A1			A2									Total	
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
11 years old	278	202	480	841	823	1,664	4	6	10	0	0	0	1,123	1,031	2,154
12 to 17 years old	6,499	5,673	12,172	17,190	16,935	34,125	208	332	540	0	0	0	23,897	22,940	46,837
18 to 24 years old	1,511	1,800	3,311	2,988	3,757	6,745	92	242	334	0	0	0	4,591	5,799	10,390
Total	8,288	7,675	15,963	21,019	21,515	42,534	304	580	884	0	0	0	29,611	29,770	59,381

Results by age group (Male)






#### Results by age group (Female)


#### Appendix 4-2: Nodule characteristics

#### As of December 31, 2024

(persons)						
de	Grad		I	Total	Nodule size	
	0.0.	Female	Male			
97.8%	A1	28,924	29,161	58,085	None	
0.7%	A2	36	21	57	≤ 3.0mm	
0.7 /0	AZ	234	127	361	3.1–5.0mm	
		367	215	582	5.1–10.0mm	
		134	55	189	10.1–15.0mm	
1.5%	В	41	20	61	15.1–20.0mm	
		17	8	25	20.1–25.0mm	
		17	4	21	≥ 25.1mm	
		29,770	29,611	59,381	Total	





□No nodules



#### Appendix 4-3: Cyst characteristics

					(persons)	
Cyst size	Total			Grade		
0,000.20		Male	Male Female Glade			
None	16,336	8,430	7,906	A1	63.0%	
≤ 3.0mm	21,089	11,326	9,763		03.0%	
3.1–5.0mm	18,300	8,548	9,752		37.0%	
5.1–10.0mm	3,573	1,288	2,285	A2		
10.1–15.0mm	71	16	55			
15.1–20.0mm	6	1	5			
20.1–25.0mm	5	2	3	В	0.01%	
≥ 25.1mm	1	0	1	В	0.01%	
Total	59,381	29,611	29,770			





As of December 31, 2024

Appendix 5: Surgery for cases malignant or suspicious for malignancy

For TUE (the sixth-round full-scale survey)	
Malignant or suspicious for malignancy:	14
	(surgical cases: 10, papillary thyroid carcinomas: 10)

## Progress of Institutional Verification for the Provision of Fukushima Health Management Survey Data to Third Parties for Academic Research Purposes

May 16, 2025 Citizens Healthcare Survey Division, Fukushima Prefecture

## 1 Progress

1-1 Prior consultation and application submission (April 2023 - January 2025)

Following the 47th Oversight Committee meeting (held in March 2023), researchers who would cooperate with institutional verification developed a research plan. This plan and an application for data provision were subsequently submitted to the Fukushima Prefectural Government. The prefectural government confirmed the plan in advance for the review meeting.

- 1-2 Holding of the Review Committee for providing Fukushima Health Management Survey data (February and March 2025): The application was reviewed, and results were reported to the prefectural government.
- 1-3 Approval of data provision (April 2025)

Based on the results of the review, the prefectural government approved the data provision.

1-4 Opt-out implementation (May-June 2025)


With consideration for the research participants, we will accept refusal requests from those who do not wish their information to be provided for research.

## 2 Future Plans

- 2-1 Data will be provided after excluding the information of those who have chosen to opt out.
- 2-2 After providing data, "publication status" shall be confirmed as appropriate. (Not only the final confirmation at the time of publication of the paper, but also the presentation of the progress of the research to persons other than the user, such as reporting within the university, shall be considered as "publication.")
- 2-3 On-site audits and other matters stipulated in the Guidelines will also be verified as necessary during the research period.

## O Reference

Implementation Flow



(Cooperating Researcher for Institutional Verification)

Researcher	Professor IMANO Hironori, Department of Public Health, KINDAI University Faculty of Medicine
Research project name	Association between evacuation, radiation doses, and the results of the Comprehensive Health Check and Mental Health and Lifestyle Survey of the Fukuhara Health Management Survey (Survey research on cardiovascular disease and its risk factors: trend analysis at the prefectural level and the regional level in Fukushima prefecture)